



APR 12 2002

TECH CENTER 1600/2900

RAW SEQUENCE LISTING
ERROR REPORT

The Biotechnology Systems Branch of the Scientific and Technical Information Center (STIC) detected errors when processing the following computer readable form:

Application Serial Number: 09/845,025B
Source: OIPE
Date Processed by STIC: 4/8/2002

THE ATTACHED PRINTOUT EXPLAINS DETECTED ERRORS.

PLEASE FORWARD THIS INFORMATION TO THE APPLICANT BY EITHER:

- 1) INCLUDING A COPY OF THIS PRINTOUT IN YOUR NEXT COMMUNICATION TO THE APPLICANT, WITH A NOTICE TO COMPLY or,
- 2) TELEPHONING APPLICANT AND FAXING A COPY OF THIS PRINTOUT, WITH A NOTICE TO COMPLY

FOR CRF SUBMISSION QUESTIONS, PLEASE CONTACT MARK SPENCER, 703-308-4212.

FOR SEQUENCE RULES INTERPRETATION, PLEASE CONTACT ROBERT WAX, 703-308-4216.

PATENTIN 2.1 e-mail help: patin21help@uspto.gov or phone 703-306-4119 (R. Wax)

PATENTIN 3.0 e-mail help: patin3help@uspto.gov or phone 703-306-4119 (R. Wax)

TO REDUCE ERRORED SEQUENCE LISTINGS, PLEASE USE THE **CHECKER** **VERSION 3.1 PROGRAM**, ACCESSIBLE THROUGH THE U.S. PATENT AND TRADEMARK OFFICE WEBSITE. SEE BELOW FOR ADDRESS:

<http://www.uspto.gov/web/offices/pac/checker>

Applicants submitting genetic sequence information electronically on diskette or CD-Rom should be aware that there is a possibility that the disk/CD-Rom may have been affected by treatment given to all incoming mail.

Please consider using alternate methods of submission for the disk/CD-Rom or replacement disk/CD-Rom.

Any reply including a sequence listing in electronic form should NOT be sent to the 20231 zip code address for the United States Patent and Trademark Office, and instead should be sent via the following to the indicated addresses:

1. EFS-Bio (<<http://www.uspto.gov/ebc/efs/downloads/documents.htm>> , EFS Submission User Manual - ePAVE)
2. U.S. Postal Service: U.S. Patent and Trademark Office, Box Sequence, P.O. Box 2327, Arlington, VA 22202
3. Hand Carry directly to:
U.S. Patent and Trademark Office, Technology Center 1600, Reception Area, 7th Floor, Examiner Name, Sequence Information, Crystal Mall One, 1911 South Clark Street, Arlington, VA 22202
Or
U.S. Patent and Trademark Office, Box Sequence, Customer Window, Lobby, Room 1B03, Crystal Plaza Two, 2011 South Clark Place, Arlington, VA 22202
4. Federal Express, United Parcel Service, or other delivery service to: U.S. Patent and Trademark Office, Box Sequence, Room 1B03-Mailroom, Crystal Plaza Two, 2011 South Clark Place, Arlington, VA 22202

RECEIVED

APR 12 2002

TECH CENTER 1600/2900

Raw Sequence Listing Error Summary

ERROR DETECTED

SUGGESTED CORRECTION

SERIAL NUMBER: 09/845,025B

ATTN: NEW RULES CASES: PLEASE DISREGARD ENGLISH "ALPHA" HEADERS, WHICH WERE INSERTED BY PTO SOFTWARE

- 1 Wrapped Nucleics
 Wrapped Aminos
The number/text at the end of each line "wrapped" down to the next line. This may occur if your file was retrieved in a word processor after creating it. Please adjust your right margin to .3; this will prevent "wrapping."
- 2 Invalid Line Length
The rules require that a line not exceed 72 characters in length. This includes white spaces.
- 3 Misaligned Amino
 Numbering
The numbering under each 5th amino acid is misaligned. Do not use tab codes between numbers; use space characters, instead.
- 4 Non-ASCII
The submitted file was not saved in ASCII(DOS) text, as required by the Sequence Rules. Please ensure your subsequent submission is saved in ASCII text.
- 5 Variable Length
Sequence(s) contain n's or Xaa's representing more than one residue. Per Sequence Rules, each n or Xaa can only represent a single residue. Please present the maximum number of each residue having variable length and indicate in the <220>-<223> section that some may be missing.
- 6 PatentIn 2.0
 "bug"
A "bug" in PatentIn version 2.0 has caused the <220>-<223> section to be missing from amino acid sequences(s) . Normally, PatentIn would automatically generate this section from the previously coded nucleic acid sequence. Please manually copy the relevant <220>-<223> section to the subsequent amino acid sequence. This applies to the mandatory <220>-<223> sections for Artificial or Unknown sequences.
- 7 Skipped Sequences
 (OLD RULES)
Sequence(s) missing. If intentional, please insert the following lines for each skipped sequence:
(2) INFORMATION FOR SEQ ID NO:X: (insert SEQ ID NO where "X" is shown)
(i) SEQUENCE CHARACTERISTICS: (Do not insert any subheadings under this heading)
(xi) SEQUENCE DESCRIPTION:SEQ ID NO:X: (insert SEQ ID NO where "X" is shown)
This sequence is intentionally skipped

Please also adjust the "(ii) NUMBER OF SEQUENCES:" response to include the skipped sequences.
- 8 Skipped Sequences
 (NEW RULES)
Sequence(s) missing. If intentional, please insert the following lines for each skipped sequence.
<210> sequence id number
<400> sequence id number
000
- 9 Use of n's or Xaa's
 (NEW RULES)
Use of n's and/or Xaa's have been detected in the Sequence Listing.
Per 1.823 of Sequence Rules, use of <220>-<223> is MANDATORY if n's or Xaa's are present.
In <220> to <223> section, please explain location of n or Xaa; and which residue n or Xaa represents.
- 10 Invalid <213>
 Response
Per 1.823 of Sequence Rules, the only valid <213> responses are: Unknown, Artificial Sequence, or scientific name (Genus/species). <220>-<223> section is required when <213> response is Unknown or is Artificial Sequence
- 11 Use of <220>
Sequence(s) missing the <220> "Feature" and associated numeric identifiers and responses.
Use of <220> to <223> is MANDATORY if <213> "Organism" response is "Artificial Sequence" or "Unknown." Please explain source of genetic material in <220> to <223> section.
(See "Federal Register," 06/01/1998, Vol. 63, No. 104, pp. 29631-32) (Sec. 1.823 of Sequence Rules)
- 12 PatentIn 2.0
 "bug"
Please do not use "Copy to Disk" function of PatentIn version 2.0. This causes a corrupted file, resulting in missing mandatory numeric identifiers and responses (as indicated on raw sequence listing). Instead, please use "File Manager" or any other manual means to copy file to floppy disk.
- 13 Misuse of n
n can only be used to represent a single nucleotide in a nucleic acid sequence. N is not used to represent any value not specifically a nucleotide.

AMC/MH - Biotechnology Systems Branch - 08/21/2001



OIPE

RAW SEQUENCE LISTING

PATENT APPLICATION: US/09/845,025B

DATE: 04/08/2002

TIME: 15:47:23

Input Set : A:\CIBT-P01-098.txt

Output Set: N:\CRF3\04082002\I845025B.raw

Does Not Comply
Corrected Diskette Needed

pp 2-4

3 <110> APPLICANT: JENNIFER OTT REILLY
 5 <120> TITLE OF INVENTION: NEUROPROTECTIVE METHODS AND COMPOSITIONS
 7 <130> FILE REFERENCE: CIBT-P01-098
 9 <140> CURRENT APPLICATION NUMBER: 09/845025B
 10 <141> CURRENT FILING DATE: 2001-04-27
 12 <150> PRIOR APPLICATION NUMBER: 60/200765
 13 <151> PRIOR FILING DATE: 2000-04-28
 15 <160> NUMBER OF SEQ ID NOS: 22
 17 <170> SOFTWARE: PatentIn Ver. 2.1

ERRORED SEQUENCES

1555 <210> SEQ ID NO: 15
 1556 <211> LENGTH: 475
 1557 <212> TYPE: PRT
 1558 <213> ORGANISM: human
 1560 <400> SEQUENCE: 15
 1561 Met Leu Leu Leu Ala Arg Cys Leu Leu Leu Val Leu Val Ser Ser Leu
 1562 1 5 10 15
 1564 Leu Val Cys Ser Gly Leu Ala Cys Gly Pro Gly Arg Gly Phe Gly Lys
 1565 20 25 30
 1567 Arg Arg His Pro Lys Lys Leu Thr Pro Leu Ala Tyr Lys Gln Phe Ile
 1568 35 40 45
 1570 Pro Asn Val Ala Glu Lys Thr Leu Gly Ala Ser Gly Arg Tyr Glu Gly
 1571 50 55 60
 1573 Lys Ile Ser Arg Asn Ser Glu Arg Phe Lys Glu Leu Thr Pro Asn Tyr
 1574 65 70 75 80
 1576 Asn Pro Asp Ile Ile Phe Lys Asp Glu Glu Asn Thr Gly Ala Asp Arg
 1577 85 90 95
 1579 Leu Met Thr Gln Arg Cys Lys Asp Lys Leu Asn Ala Leu Ala Ile Ser
 1580 100 105 110
 1582 Val Met Asn Gln Trp Pro Gly Val Lys Leu Arg Val Thr Glu Gly Trp
 1583 115 120 125
 1585 Asp Glu Asp Gly His His Ser Glu Glu Ser Leu His Tyr Glu Gly Arg
 1586 130 135 140
 1588 Ala Val Asp Ile Thr Thr Ser Asp Arg Asp Arg Ser Lys Tyr Gly Met
 1589 145 150 155 160
 1591 Leu Ala Arg Leu Ala Val Glu Ala Gly Phe Asp Trp Val Tyr Tyr Glu
 1592 165 170 175
 1594 Ser Lys Ala His Ile His Cys Ser Val Lys Ala Glu Asn Ser Val Ala
 1595 180 185 190
 1597 Ala Lys Ser Gly Gly Cys Phe Pro Gly Ser Ala Thr Val His Leu Glu

RAW SEQUENCE LISTING

PATENT APPLICATION: US/09/845,025B

DATE: 04/08/2002

TIME: 15:47:24

Input Set : A:\CIBT-P01-098.txt

Output Set: N:\CRF3\04082002\I845025B.raw

```

1598          195          200          205
1600 Gln Gly Gly Thr Lys Leu Val Lys Asp Leu Ser Pro Gly Asp Arg Val
1601          210          215          220
1603 Leu Ala Ala Asp Asp Gln Gly Arg Leu Leu Tyr Ser Asp Phe Leu Thr
1604 225          230          235          240
1606 Phe Leu Asp Arg Asp Asp Gly Ala Lys Lys Val Phe Tyr Val Ile Glu
1607          245          250          255
1609 Thr Arg Glu Pro Arg Glu Arg Leu Leu Leu Thr Ala Ala His Leu Leu
1610          260          265          270
1612 Phe Val Ala Pro His Asn Asp Ser Ala Thr Gly Glu Pro Glu Ala Ser
1613          275          280          285
1615 Ser Gly Ser Gly Pro Pro Ser Gly Gly Ala Leu Gly Pro Arg Ala Leu
1616          290          295          300
1618 Phe Ala Ser Arg Val Arg Pro Gly Gln Arg Val Tyr Val Val Ala Glu
1619 305          310          315          320
1621 Arg Asp Gly Asp Arg Arg Leu Leu Pro Ala Ala Val His Ser Val Thr
1622          325          330          335
1624 Leu Ser Glu Glu Ala Ala Gly Ala Tyr Ala Pro Leu Thr Ala Gln Gly
1625          340          345          350
1627 Thr Ile Leu Ile Asn Arg Val Leu Ala Ser Cys Tyr Ala Val Ile Glu
1628          355          360          365
1630 Glu His Ser Trp Ala His Arg Ala Phe Ala Pro Phe Arg Leu Ala His
1631          370          375          380
1633 Ala Leu Leu Ala Ala Leu Ala Pro Ala Arg Thr Asp Arg Gly Gly Asp
1634 385          390          395          400
1636 Ser Gly Gly Gly Asp Arg Gly Gly Gly Gly Arg Val Ala Leu Thr
1637          405          410          415
1639 Ala Pro Gly Ala Ala Asp Ala Pro Gly Ala Gly Ala Thr Ala Gly Ile
1640          420          425          430
1642 His Trp Tyr Ser Gln Leu Leu Tyr Gln Ile Gly Thr Trp Leu Leu Asp
1643          435          440          445
E--> 1645 Ser Glu Ala Leu His Pro Leu Gly Met Ala Val Lys Ser Ser Xaa Ser
1646          450          455          460
1648 Arg Gly Ala Gly Gly Gly Ala Arg Glu Gly Ala
1649 465          470          475
2138 <210> SEQ ID NO: 21
2139 <211> LENGTH: 221
2140 <212> TYPE: PRT
2141 <213> ORGANISM: human
2143 <400> SEQUENCE: 21
E--> 2144 Cys Gly Pro Gly Arg Gly Xaa Gly Xaa Arg Arg His Pro Lys Lys Leu
2145 1          5          10          15
2147 Thr Pro Leu Ala Tyr Lys Gln Phe Ile Pro Asn Val Ala Glu Lys Thr
2148          20          25          30
E--> 2150 Leu Gly Ala Ser Gly Arg Tyr Glu Gly Lys Ile Xaa Arg Asn Ser Glu
2151          35          40          45
2153 Arg Phe Lys Glu Leu Thr Pro Asn Tyr Asn Pro Asp Ile Ile Phe Lys
2154          50          55          60
2156 Asp Glu Glu Asn Thr Gly Ala Asp Arg Leu Met Thr Gln Arg Cys Lys

```

see item 9 on
Error Summary
sheet

see p. 3, too

see
item 9

RAW SEQUENCE LISTING

PATENT APPLICATION: US/09/845,025B

DATE: 04/08/2002

TIME: 15:47:24

Input Set : A:\CIBT-P01-098.txt

Output Set: N:\CRF3\04082002\I845025B.raw

```

2157 65      70      75      80
E--> 2159 Asp Lys Leu Asn Xaa Leu Ala Ile Ser Val Met Asn Xaa Trp Pro Gly
2160      85      90      95
E--> 2162 Val Xaa Leu Arg Val Thr Glu Gly Trp Asp Glu Asp Gly His His Xaa
2163      100      105      110
2165 Glu Glu Ser Leu His Tyr Glu Gly Arg Ala Val Asp Ile Thr Thr Ser
2166      115      120      125
E--> 2168 Asp Arg Asp Xaa Ser Lys Tyr Gly Xaa Leu Xaa Arg Leu Ala Val Glu
2169      130      135      140
2171 Ala Gly Phe Asp Trp Val Tyr Tyr Glu Ser Lys Ala His Ile His Cys
2172 145      150      155      160
2174 Ser Val Lys Ala Glu Asn Ser Val Ala Ala Lys Ser Gly Gly Cys Phe
2175      165      170      175
E--> 2177 Pro Gly Ser Ala Xaa Val Xaa Leu Xaa Xaa Gly Gly Xaa Lys Xaa Val
2178      180      185      190
E--> 2180 Lys Asp Leu Xaa Pro Gly Asp Xaa Val Leu Ala Ala Asp Xaa Xaa Gly
2181      195      200      205
E--> 2183 Xaa Leu Xaa Xaa Ser Asp Phe Xaa Xaa Phe Xaa Asp Arg
2184      210      215      220
2186 <210> SEQ ID NO: 22
2187 <211> LENGTH: 167
2188 <212> TYPE: PRT
2189 <213> ORGANISM: human
2191 <400> SEQUENCE: 22
E--> 2192 Cys Gly Pro Gly Arg Gly Xaa Xaa Xaa Arg Arg Xaa Xaa Xaa Pro Lys
2193 1 5 10 15
E--> 2195 Xaa Leu Xaa Pro Leu Xaa Tyr Lys Gln Phe Xaa Pro Xaa Xaa Xaa Glu
2196 20 25 30
E--> 2198 Xaa Thr Leu Gly Ala Ser Gly Xaa Xaa Glu Gly Xaa Xaa Xaa Arg Xaa
2199 35 40 45
E--> 2201 Ser Glu Arg Phe Xaa Xaa Leu Thr Pro Asn Tyr Asn Pro Asp Ile Ile
2202 50 55 60
E--> 2204 Phe Lys Asp Glu Glu Asn Xaa Gly Ala Asp Arg Leu Met Thr Xaa Arg
2205 65 70 75 80
E--> 2207 Cys Lys Xaa Xaa Xaa Asn Xaa Leu Ala Ile Ser Val Met Asn Xaa Trp
2208 85 90 95
E--> 2210 Pro Gly Val Xaa Leu Arg Val Thr Glu Gly Xaa Asp Glu Asp Gly His
2211 100 105 110
E--> 2213 His Xaa Xaa Xaa Ser Leu His Tyr Glu Gly Arg Ala Xaa Asp Ile Thr
2214 115 120 125
E--> 2216 Thr Ser Asp Arg Asp Xaa Xaa Lys Tyr Gly Xaa Leu Xaa Arg Leu Ala
2217 130 135 140
E--> 2219 Val Glu Ala Gly Phe Asp Trp Val Tyr Tyr Glu Ser Xaa Xaa His Xaa
2220 145 150 155 160
E--> 2222 His Xaa Ser Val Lys Xaa Xaa
2223 165

```

*see
item 9*

*see
item 9*

VARIABLE LOCATION SUMMARY
PATENT APPLICATION: US/09/845,025B

DATE: 04/08/2002
TIME: 15:47:25

Input Set : A:\CIBT-P01-098.txt
Output Set: N:\CRF3\04082002\I845025B.raw

Use of n's or Xaa's(NEW RULES):

Use of n's and/or Xaa's have been detected in the Sequence Listing.
Use of <220> to <223> is MANDATORY if n's or Xaa's are present.
in <220> to <223> section, please explain location of n or Xaa, and which
residue n or Xaa represents.

Seq#:6; N Pos. 1387,1388,1389

Seq#:6; Xaa Pos. 463

Seq#:15; Xaa Pos. 463

Seq#:21; Xaa Pos. 7,9,44,85,93,98,112,132,137,139,181,183,185,186,189,191

Seq#:21; Xaa Pos. 196,200,206,207,209,211,212,216,217,219

Seq#:22; Xaa Pos. 7,8,9,12,13,14,17,19,22,27,29,30,31,33,40,41,44,45,46,48

Seq#:22; Xaa Pos. 53,54,71,79,83,84,85,87,95,100,107,114,115,116,125,134

Seq#:22; Xaa Pos. 135,139,141,157,158,160,162,166,167